Antibiotic treatment is associated with reduced risk of a subsequent exacerbation in obstructive lung disease: an historical population based cohort study

Roede, B. M.; Bresser, P.; Bindels, P. J. E.; Kok, A.; Prins, M.; tel Riet, G.; Geskus, R. B.; Herings, R. M. C.; Prins, J. M.
November 2008
Thorax;Nov2008, Vol. 63 Issue 11, p968
Academic Journal
Objectives: The risk of a subsequent exacerbation after treatment of an exacerbation with oral corticosteroids without (OS) or with (USA) antibiotics was evaluated in a historical population based cohort study comprising patients using maintenance medication for obstructive lung disease. Methods: The Pharmo database includes drug dispensing records of more than 2 million subjects in The Netherlands. Eligible were patients ⩾50 years who in 2003 were dispensed ⩾2 prescriptions of daily used inhaled β2 agonists, anticholinergics and/or corticosteroids, and experienced at least one exacerbation before 1 January 2006. Exacerbation was defined as a prescription of OS or USA. The times to the second and third exacerbations were compared using Kaplan-Meier survival analysis. Independent determinants of new exacerbations were identified using multivariable Cox recurrent event survival analysis. Results: Of 49 599 patients using maintenance medication, 18 928 had at least one exacerbation; in 52%, antibiotics had been added. The OS and USA groups were comparable for potential confounding factors. Median time to the second exacerbation was 321 days in the OS group and 418 days in the USA group (p<0.001); and between the second and third exacerbation 127 vs 240 days (p<0.001). The protective effect of USA was most pronounced during the first 3 months following treatment (hazard ratio (HR) 0.62; 99% CI 0.60 to 0.65). In the USA group, mortality during follow-up was lower (HR 0.82; 99% CI 0.66 to 0.98). Conclusion: Treatment with antibiotics in addition to oral corticosteroids was associated with a longer time to the next exacerbation, and a decreased risk of developing a new exacerbation.


Related Articles

  • Should Inhaled Corticosteroids be Used in the Long Term Treatment of Chronic Obstructive Pulmonary Disease? Burge, S. // Drugs;Aug2001, Vol. 61 Issue 11, p1535 

    Chronic obstructive pulmonary disease (COPD) is a progressive disease with alveolar destruction (emphysema) and bronchiolar fibrosis (obstructive bronchitis) in variable proportions. Reducing disease progression, as assessed by forced expiratory volume in 1 second (FEV) decline, health-related...

  • Risk of herpes zoster among patients with chronic obstructive pulmonary disease: a population-based study. Yang, Ya-Wen; Chen, Yi-Hua; Wang, Kuo-Hsien; Wang, Chen-Yi; Lin, Hui-Wen // CMAJ: Canadian Medical Association Journal;3/22/2011, Vol. 183 Issue 5, pE275 

    Background: Systemic inflammation and dysregulated immune function in chronic obstructive pulmonary disease (COPD) is hypothesized to predispose patients to development of herpes zoster. However, the risk of herpes zoster among patients with COPD is undocumented. We therefore aimed to...

  • COPD exacerbations · 5: Management. Rodríguez-Roisin, R. // Thorax;Jun2006, Vol. 61 Issue 6, p535 

    The article presents a review of the most crucial evidence based therapeutic options for the management of exacerbations of Chronic Obstructive Pulmonary Disease (COPD). Exacerbations of COPD have the characteristics of enhanced airway inflammation and oedema and systemic inflammation, leading...

  • Inhaled corticosteroids don't increase nonvertebral fracture risk.  // Reactions Weekly;1/29/2005, Issue 1036, p5 

    Presents the results of a study on the association between the use of inhaled corticosteroids and the risk of nonvertebral fractures in patients with chronic obstructive pulmonary disease in the U.S. Comparison between patients with a treated nonvertebral fracture and patients who served as the...

  • New study allays fear over inhaled steroids. Pedder, Cato // Pulse;11/10/2003, Vol. 63 Issue 45, p17 

    Reports on the results of the study examining the effects of inhaled corticosteroids in patients with asthma or chronic obstructive pulmonary disease (COPD) in the U.S. Tendency of COPD to lead to decrease in bone mineral density; Indication that the inhaled steroids slow lung function decline...

  • Inhaled Corticosteroids, Bone Mineral Density and Fracture in Older People. Hubbard, Richard; Tattersfield, Anne // Drugs & Aging;2004, Vol. 21 Issue 10, p631 

    The efficacy of inhaled corticosteroids in the treatment of asthma has been firmly established in a variety of settings. The majority of asthma management plans now recommend the use of inhaled corticosteroids at an early stage. This means that most patients with asthma will be prescribed an...

  • Efficacy of Corticosteroids in Acute Exacerbations of COPD. Sadovsky, Richard // American Family Physician;3/1/2004, Vol. 69 Issue 5, p1266 

    Examines the efficacy of corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Influence of corticosteroids on forced expiratory volume; Significance of corticosteroids to lung function; Outcome of corticosteroid treatment.

  • Predictors of Adherence to Inhaled Medications Among Veterans with COPD. Huetsch, John; Uman, Jane; Udris, Edmunds; Au, David // JGIM: Journal of General Internal Medicine;Nov2012, Vol. 27 Issue 11, p1506 

    BACKGROUND: Factors contributing to medication nonadherence among patients with chronic obstructive pulmonary disease (COPD) are poorly understood. OBJECTIVES: To identify patient characteristics that are predictive of adherence to inhaled medications for COPD and, for patients on multiple...

  • Impact of Long-Acting Bronchodilators and Exposure to Inhaled Corticosteroids on Mortality in COPD: A Real-Life Retrospective Cohort Study. Manoharan, Arvind; Short, Phillip; Anderson, William; Lipworth, Brian // Lung;Oct2014, Vol. 192 Issue 5, p649 

    The article presents research on the impact of long-acting bronchodilator therapy and associated exposure to inhaled corticosteroids (ICS) on all-cause and cardiovascular mortality in patients with chronic obstructive pulmonary disease (COPD). Treatment of COPD with long-acting muscarinic...


Read the Article


Sign out of this library

Other Topics